Although conventional imaging modalities for the initial staging of prostate cancer include Computed Tomography/Magnetic Resonance (CT/MR) and whole body bone scintigraphy [2], Gallium 68 (68Ga) Prostate Specific Membrane Antigen (PSMA) Position Emission Tomography/Computed Tomography (PET/CT), a method with higher sensitivity and specificity in distant lymph node metastasis and bone metastasis compared to conventional imaging modalities, has been used since 2012 [3,4]. The gene discussed is FOLH1; the disease is prostate carcinoma.